Published: Mar 09, 2021
–Announced new positive data in human experimental model of inflammation of EDP1815–
–Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021–
–Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021–
–Up to 8 clinical data readouts expected over next 18 months–
–Management to host conference call at 8:30 a.m. ET–
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the fourth quarter and full year 2020.